Phase 2 trial to determine the efficacy, safety, and feasibility of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSCILLATE
- 10 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 22 May 2017 New trial record